• SUNOSI® (solriamfetol)

  
  

  AXSOME THERAPEU

  Sunosi Is Indicated To Improve Wakefulness In Adults With Excessive Daytime Sleepiness (Eds) Associated With Narcolepsy Or Obstructive Sleep Apnea (Osa).

  

• REXULTI® (brexpiprazole) marketed by Otsuka America Pharmaceutical, Inc. and Lundbeck

  
  

  OTSUKA AMERICA

  Rexulti Is Indicated For Treatment Of Agitation Associated With Dementia Due To Alzheimer’S Disease. Limitations Of Use: Rexulti Is Not Indicated As An As Needed (“Prn”) Treatment For Agitation Associated With Dementia Due To Alzheimer’S Disease.

  

• JEMPERLI (dostarlimab-gxly) sponsored by GSK

  
  

  GLAXOSMITHKLINE

  Jemperli, In Combination With Carboplatin And Paclitaxel, Followed By Jemperli As A Single Agent, Is Indicated For The Treatment Of Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer (Ec). Jemperli, As A Single Agent, Is Indicated For The Treatment Of Adult Patients With Mismatch Repair Deficient (Dmmr) Recurrent Or Advanced: Ec, As Determined By An Fda-Approved Test, That Has Progressed On Or Following Prior Treatment With A Platinum-Containing Regimen In Any Setting And

  

• KISQALI® (ribociclib) sponsored by Novartis Pharmaceuticals Corporation

  
  

  NOVARTIS

  Kisqali Is Indicated For The Treatment Of Adult Patients With Hormone Receptor (Hr)-Positive, Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Or Metastatic Breast Cancer In Combination With: An Aromatase Inhibitor As Initial Endocrine-Based Therapy; Or Fulvestrant As Initial Endocrine-Based Therapy Or Following Disease Progression On Endocrine Therapy In Postmenopausal Women Or In Men.

  

• OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) sponsored by Bristol-Myers Squibb

  
  

  BMS PRIMARYCARE

  Opdivo Qvantig Is A Combination Of Nivolumab, A Programmed Death Receptor-1 (Pd-1)-Blocking Antibody, And Hyaluronidase, An Endoglycosidase, Indicated For The Treatment Of

  

• KEYTRUDA® (pembrolizumab) is sponsored by Merck.

  
  

  MERCK SHARP & D

  Adjuvant Therapy For Melanoma Keytruda Is Indicated For The Adjuvant Treatment Of Adult And Pediatric (12 Years And Older) Patients With Stage Iib, Iic, Or Iii Melanoma Following Complete Resection. Adjuvant Treatment For Renal Cell Carcinoma (Rcc) Keytruda Is Indicated For The Adjuvant Treatment Of Patients With Renal Cell Carcinoma (Rcc) At Intermediate-High Or High Risk Of Recurrence Following Nephrectomy, Or Following Nephrectomy And Resection Of Metastatic Lesions.

  

• OGSIVEO® (nirogacestat) Resource Page, Sponsored by SpringWorks Therapeutics Inc.

  
  

  SPRINGWORKS THE

  Ogsiveo Is Indicated For Adult Patients With Progressing Desmoid Tumors Who Require Systemic Treatment.

  

• Wegovy® (semaglutide) injection 2.4 mg, sponsored by Novo Nordisk

  
  

  NOVO NORDISK

  Indicated In Combination With A Reduced Calorie Diet And Increased Physical Activity:To Reduce The Risk Of Major Adverse Cardiovascular Events (Cardiovascular Death, Non-Fatal Myocardial Infarction, Or Non-Fatal Stroke) In Adults With Established Cardiovascular Disease And Either Obesity Or Overweight To Reduce Excess Body Weight And Maintain Weight Reduction Long Term In Adults And Pediatric Patients Aged 12 Years And Older With Obesity And Adults With Overweight In The Presence Of At Least

  

• VOWST (fecal microbiota spores, live-brpk) capsules, sponsored by Nestle Health Sciences and Seres Therapeutics

  
  

  NESTLE-SERES

  Vowst Is A Prescription Medicine Used To Prevent Clostridioides Difficile (C. Diff) Infection From Coming Back In People 18 Years Of Age Or Older After Antibiotic Treatment For C. Diff Infection Has Been Completed.

  

• SYFOVRE® (pegcetacoplan injection), sponsored by Apellis Pharmaceuticals, Inc.

  
  

  APELLIS PHARMAC

  Syfovre® (Pegcetacoplan Injection) Is Indicated For The Treatment Of Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration (Amd).

  

• PRIVIGEN®, Immune Globulin Intravenous (Human), 10% Liquid

  
  

  CSL BEHRING LLC

  Privigen Is Indicated For The Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) In Adults. Limitation Of Use: Maintenance Therapy In Cidp Has Not Been Studied For Periods Longer Than 6 Months. Individualize Duration Of Treatment Beyond 6 Months Based On Patient Response.

  

• LIBTAYO® (cemiplimab-rwlc) Injection 350mg by Regeneron Pharmaceuticals, Inc.

  
  

  REGENERON PHARM

  Libtayo Is Indicated For The Treatment Of Patients With Metastatic Cutaneous Squamous Cell Carcinoma (Cscc) Or Locally Advanced Cscc Who Are Not Candidates For Curative Surgery Or Curative Radiation.

  

• AUVELITY® (dextromethorphan hydrobromide and bupropion hydrochloride) by Axsome Therapeutics, Inc.

  
  

  AXSOME THERAPEU

  Auvelity Is Indicated For The Treatment Of Major Depressive Disorder (Mdd) In Adults.

  

• Omvoh (mirikizumab-mrkz)

  
  

  LILLY

  Omvoh Mirikizumab-Mrkz 300 Mg/15 Ml Infusion, 100 Mg/Ml Injection] Is Indicated For The Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis.

  

• FOTIVDA® (tivozanib) sponsored by AVEO Oncology, an LG Chem company.

  
  

  AVEO PHARMACEUT

  Fotivda Is Indicated For The Treatment Of Adult Patients With Relapsed Or Refractory Advanced Renal Cell Carcinoma (Rcc) Following Two Or More Prior Systemic Therapies.

  

• Jakafi® (ruxolitinib) - Incyte Corporation

  
  

  Incyte Corporation

  Jakafi Is Indicated For Treatment Of Intermediate Or High-Risk Myelofibrosis, Including Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis And Post-Essential Thrombocythemia Myelofibrosis In Adults, And, Polycythemia Vera In Adults Who Have Had An Inadequate Response To Or Are Intolerant Of Hydroxyurea, And Steroid-Refractory Acute Graft-Versus-Host Disease In Adult And Pediatric Patients 12 Years And Older.

  

• LEQEMBI® (lecanemab-irmb) sponsored by Eisai Inc. and Biogen.

  
  

  EISAI INC.

  Leqembi Is Indicated For The Treatment Of Alzheimer’S Disease. Treatment With Leqembi Should Be Initiated In Patients With Mild Cognitive Impairment Or Mild Dementia Stage Of Disease, The Population In Which Treatment Was Initiated In Clinical Trials.

  

• Jaypirca (Pirtobrutinib)

  
  

  ELI LILLY & CO.

  Jaypirca Is A Kinase Inhibitor Indicated For The Treatment Of Adult Patients With Relapsed Or Refractory (R/R) Mantle Cell Lymphoma (Mcl) After At Least Two Lines Of Systemic Therapy, Including A Btk Inhibitor.